Project Leader: Valentina Kon, M.D.
Co-Investigator: Patricia Yancey, Ph.D.
Statistician: Ayumi Kamina Shintani, Ph.D.
Consultant: Sergio Fazio, M.D., Ph.D.
Although chronic kidney disease (CKD) causes dyslipidemia, its pattern does not necessarily fit into recommendations for therapeutic interventions in the general population and belies profound disturbances in the lipid metabolism and function. These studies will determine the mechanisms and thus potential therapeutic targets by which high density lipoprotein (HDL) disrupts basic biological processes that underlie a host of abnormalities that plague children with CKD, including cardiac disease, hypertension, impaired inflammatory response.
© 2010-2018. All Rights Reserved to Vanderbilt University. Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Released April 5, 2018